Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection

Sheng-Min Wang1 International Health Care Center, Seoul St Mary’s Hospital, The Catholic University of Korea, College of Medicine, Seoul, Republic of Korea

Changsu Han2 Department of Psychiatry, College of Medicine, Korea University, Seoul, Republic of Korea

Soo-Jung Lee5 Department of Psychiatry, Bucheon St Mary’s Hospital, The Catholic University of Korea, College of Medicine, Seoul, Republic of Korea

Ashwin A Patkar3 Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA

Prakash S Masand4 Global Medical Education, New York, NY, USA

Chi-Un Pae3 Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA;5 Department of Psychiatry, Bucheon St Mary’s Hospital, The Catholic University of Korea, College of Medicine, Seoul, Republic of KoreaCorrespondence[email protected]

Pages 1605-1611 | Published online: 30 Aug 2014

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

TiihonenJHaukkaJTaylorMHaddadPMPatelMXKorhonenPA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaAm J Psychiatry201116860360921362741
PubMed Web of Science ®Google Scholar
GoreishizadehMMohagheghiAFarhangSAlizadehLPsychosocial disabilities in patients with schizophreniaIran J Public Health20124111612123113186
PubMed Web of Science ®Google Scholar
LeuchtSTardyMKomossaKHeresSKisslingWDavisJMMaintenance treatment with antipsychotic drugs for schizophreniaCochrane Database Syst Rev20125CD00801622592725
PubMed Web of Science ®Google Scholar
NovickDHaroJMSuarezDPerezVDittmannRWHaddadPMPredictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophreniaPsychiatry Res201017610911320185182
PubMed Web of Science ®Google Scholar
AcostaFJHernandezJLPereiraJHerreraJRodriguezCJMedication adherence in schizophreniaWorld J Psychiatry20122748224175171
PubMedGoogle Scholar
BitterIKatonaLZamboriJComparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in HungaryEur Neuropsychopharmacol2013231383139023477752
PubMed Web of Science ®Google Scholar
WeidenPRapkinBZygmuntAMottTGoldmanDFrancesAPostdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimenPsychiatr Serv199546104910548829787
PubMed Web of Science ®Google Scholar
WeidenPJOlfsonMCost of relapse in schizophreniaSchizophr Bull1995214194297481573
PubMed Web of Science ®Google Scholar
LafeuilleMHGravelJLefebvrePPatterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychoticsJ Med Econ2013161290129924006903
PubMedGoogle Scholar
KaneJMImproving treatment adherence in patients with schizophreniaJ Clin Psychiatry201172e2821951990
PubMedGoogle Scholar
MarcusSCOlfsonMOutpatient antipsychotic treatment and inpatient costs of schizophreniaSchizophr Bull20083417318017578893
PubMed Web of Science ®Google Scholar
LoveRCConleyRJLong-acting risperidone injectionAm J Health Syst Pharm2004611792180015462250
PubMed Web of Science ®Google Scholar
NussbaumAMStroupTSPaliperidone palmitate for schizophreniaCochrane Database Syst Rev20126CD00829622696377
PubMed Web of Science ®Google Scholar
FramptonJEOlanzapine long-acting injection: a review of its use in the treatment of schizophreniaDrugs2010702289231321080745
PubMed Web of Science ®Google Scholar
MotiwalaFBSiscoeKSEl-MallakhRSReview of depot aripiprazole for schizophreniaPatient Prefer Adherence201371181118724265550
PubMed Web of Science ®Google Scholar
MallikaarjunSKaneJMBricmontPPharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose studySchizophr Res201315028128823890595
PubMed Web of Science ®Google Scholar
Otsuka Pharmaceutical Co LtdAbilify Maintena™ (aripiprazole) extended release injectable suspension, package insertTokyo, JapanOtsuka Pharmaceutical Co Ltd Available from: http://www.otsuka-us.com/Products/Documents/Abilify.M.PI.pdfAccessed April 23, 2014
Google Scholar
PaeCUA review of the safety and tolerability of aripiprazoleExpert Opin Drug Saf2009837338619505266
PubMed Web of Science ®Google Scholar
BurrisKDMolskiTFXuCAripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptorsJ Pharmacol Exp Ther200230238138912065741
PubMed Web of Science ®Google Scholar
JordanSKoprivicaVChenRTottoriKKikuchiTAltarCAThe antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptorEur J Pharmacol200244113714012063084
PubMed Web of Science ®Google Scholar
KaneJMSanchezRPerryPPAripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychiatry20127361762422697189
PubMed Web of Science ®Google Scholar
CitromeLNew second-generation long-acting injectable antipsychotics for the treatment of schizophreniaExpert Rev Neurother20131376778323898849
PubMed Web of Science ®Google Scholar
KaneJMSanchezRZhaoJHospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophreniaJ Med Econ20131691792523663091
PubMedGoogle Scholar
FleischhackerWWSanchezRAripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority studyBr J PsychiatryIn press2014
Web of Science ®Google Scholar
RauchASFleischhackerWWLong-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspectiveCNS Drugs20132763765223780619
PubMed Web of Science ®Google Scholar
FleischhackerWWSanchezRJohnsonBLong-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophreniaInt Clin Psychopharmacol20132817117623615694
PubMed Web of Science ®Google Scholar
PotkinSGRaoufiniaAMallikaarjunSSafety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazoleCurr Med Res Opin2013291241125123822566
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date